Payer Perspectives on Gene Therapy Reimbursement

Eric NormanArticles, FoCUS

J.F. Barlow; M.W. Courtney; M. Trusheim. Pharmaceutical Executive, 04/2020

The reimbursement of emerging durable and potentially curative cell and gene therapies challenge US payers due to their high upfront costs. In addition, the lack of long-term clinical durability data amplifies uncertainties that complicate payer coverage and reimbursement determinations. These cell and gene therapy characteristics could negatively impact patient access and, ultimately, future developer innovation.

Read the article